This report gives broad information on the medicinal change for Attention Deficit Hyperactivity Disorder (ADHD), complete with close examination at diverse stages, therapeutics assessment by drug target, instrument of action (MoA), course of association (RoA) and molecule sort, nearby latest overhauls, and highlighted news and press releases. It moreover reviews key players included in the remedial progression for Attention Deficit Hyperactivity Disorder (ADHD) and novel components on late-stage and halted assignments

1. Browse more Reports on Neurology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-
therapeutics .
Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2015
By
RnRMarketResearch.com
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Publisher Name : Global Markets Direct
Date: 24-Jun-2015
No. of pages: 182
Single User License: US $2000

2. This report gives broad information on the medicinal change for Attention Deficit
Hyperactivity Disorder (ADHD), complete with close examination at diverse stages,
therapeutics assessment by drug target, instrument of action (MoA), course of
association (RoA) and molecule sort, nearby latest overhauls, and highlighted news
and press releases. It moreover reviews key players included in the remedial
progression for Attention Deficit Hyperactivity Disorder (ADHD) and novel
components on late-stage and halted assignments.
The report updates decision making limits and help to make capable counter
philosophies to build high ground. It braces R&D pipelines by recognizing new
targets and MOAs to make first-in-class and best-in-class things.
Attention Deficit Hyperactivity Disorder -
Pipeline Review, H1 2015
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441

3. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Attention Deficit Hyperactivity Disorder -
Pipeline Review, H1 2015
Companies Discussed/Mentioned in this Research:
Alcobra Ltd, Amarantus Bioscience Holdings, Inc., Arbor Pharmaceuticals, LLC., Cerecor
Inc., Collegium Pharmaceutical, Inc., Curemark, LLC, DURECT Corporation, Eli Lilly and
Company, H. Lundbeck A/S, Hisamitsu Pharmaceutical Co., Inc., Integrative Research
Laboratories Sweden AB, Intra-Cellular Therapies, Inc., KemPharm, Inc., Merck & Co., Inc.,
Mnemosyne Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd. And more
Drugs Profile Discussed in this Research :
AR-08, BLI-1008, BNC-375, brexpiprazole, centanafadine IR, centanafadine SR, CM-4612,
CTX-1301, CTX-1302, dasotraline, dextroamphetamine, dextroamphetamine MR, Drug for
Attention Deficit Hyperactivity Disorder, edivoxetine, eltoprazine, etiguanfacine,
guanfacine hydrochloride ER, HTL-1071, IRL-752, ITI-214, KP-415 CR, lisdexamfetamine
dimesylate, Metadoxine ER, methylphenidate, methylphenidate hydrochloride,
methylphenidate hydrochloride and more

4. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Scope For Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2015
• The report provides a snapshot of the global therapeutic landscape of Attention
Deficit Hyperactivity Disorder (ADHD)
• The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
• The report reviews key players involved in the therapeutics development for
Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and
minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
Attention Deficit Hyperactivity Disorder -
Pipeline Review, H1 2015

5. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and
insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading
companies
• Identify and understand important and diverse types of therapeutics
under development for Attention Deficit Hyperactivity Disorder (ADHD)
• Plan mergers and acquisitions effectively by identifying key players of
the most promising pipeline
• Devise corrective measures for pipeline projects by understanding
Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and
focus of Indication therapeutics
Attention Deficit Hyperactivity Disorder -
Pipeline Review, H1 2015

6. For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441
RnRMarkertResearch
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Attention Deficit Hyperactivity Disorder -
Pipeline Review, H1 2015